Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults with familial chylomicronemia syndrome. In July 2026, Sanofi announced that…
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal nocturnal hemoglobinuria (PNH). On July 23, 2026, China’s National Medical…
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying mechanism of Type 1 narcolepsy (NT1). On July 21, 2026,…
Izalontamab Brengitecan is the first approved ADC for esophageal squamous cell carcinoma (ESCC) worldwide. It is also the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate (ADC), independently developed by Chinese biopharmaceutical company Biokin Pharmaceutical. On…
On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing. Adamgammadex sodium approved by NMPA marks a major milestone as the world’s second and China’s first domestically developed targeted neuromuscular…
On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in China for mild to moderate Alzheimer’s disease, marking another milestone in China’s neurological drug innovation. Alzheimer’s disease (AD) is the…
On July 9, 2026, China officially released the China National Essential Medicines List 2026, adding 116 medicines and bringing the total to 794. The updated list, the first revision since 2018, will take effect on…
On June 22, 2026, China’s National Medical Products Administration (NMPA) officially approved Eli Lilly’s innovative Class 1 drug Imlunestrant (brand name: Inluriyo). The drug is the first and currently only approved oral SERD in China,…
On June 22, 2026, China’s National Medical Products Administration (NMPA) officially approved Silevimig Injection (Jinsuxi®), independently developed by Genrix Biopharmaceutical, for rabies passive immunization in adults following exposure to Rabies Virus (RABV). The approval of…
On June 22, 2026, China’s National Medical Products Administration (NMPA) approved Satricabtagene Autoleucel (Kailimei®), developed by CARsgen Therapeutics, for the treatment of patients with CLDN18.2-positive, HER2-negative advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who…
On June 22, 2026, NMPA officially approved Biokin Pharmaceutical’s independently developed Class 1 innovative drug, Izalontamab Brengitecan (brand name: Yizekang), for marketing in China. It is indicated for adult patients with recurrent or metastatic nasopharyngeal…
On June 11, China’s National Medical Products Administration (NMPA) officially approved Wuhan Createrna Science and Technology’s self-developed lanoracopan hydrochloride tablets (Yishining®) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not…
